INM (InMed Pharmaceuticals) FCF Margin % : -225.00% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InMed Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2024 was $-2.50 Mil. InMed Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $1.11 Mil. Therefore, InMed Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2024 was -225.00%.

As of today, InMed Pharmaceuticals's current FCF Yield % is -324.96%.

The historical rank and industry rank for InMed Pharmaceuticals's FCF Margin % or its related term are showing as below:

INM' s FCF Margin % Range Over the Past 10 Years
Min: -1434.62 Med: -180 Max: -150.88
Current: -150.88

During the past 13 years, the highest FCF Margin % of InMed Pharmaceuticals was -150.88%. The lowest was -1434.62%. And the median was -180.00%.

INM's FCF Margin % is ranked worse than
92.25% of 981 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs INM: -150.88

InMed Pharmaceuticals FCF Margin % Historical Data

The historical data trend for InMed Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals FCF Margin % Chart

InMed Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-1,434.62

-180.00

-152.13

InMed Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-149.03	-164.88	-80.20	-144.43	-225.00

Competitive Comparison of InMed Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's FCF Margin % falls into.

Save Embed

;

Save Embed

;

InMed Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

InMed Pharmaceuticals's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-6.995	/	4.598
	=	-152.13 %

InMed Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.502	/	1.112
	=	-225.00 %

InMed Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MWG:Germany MWG:Germany

Address

885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Executives

Mancini Alexandra Diane Janet	officer: Sr VP, Clinical Reg Affairs	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Andrew Hull	director	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Eric A Adams	director, officer: President & CEO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Jonathan Tegge	officer: Interim CFO	217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li	officer: VP, Accounting and Controller	310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Brenda Edwards	officer: Interim CFO	111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove	director	510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill	officer: CFO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson	officer: SVP & GM of BayMedica LLC	930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler	director	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu	officer: Sr. VP, Pre-Clinical Res/Dev	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4